Healthcare >> CEO Interviews >> January 10, 2001
DONALD L. DRAKEMAN, JD, PhD is President and CEO of Medarex, Inc., a
Nasdaq-listed biotechnology company developing monoclonal antibodies for
the treatment of a wide range of life threatening and debilitating
diseases. He previously served as Vice President and General Counsel of
Essex Chemical Corporation, a NYSE-listed company, and President of
Essex Medical Products, Inc. He also served as an Attorney at Milbank,
Tweed, Hadley & McCloy and as a faculty member at Princeton University.
He is a Director of Oxford GlycoSciences Plc and Immuno-Designed
Molecules, SA; he is also a member of the Board of Directors of the
Biotechnology Industry Organization and has served as Chairman of the
Biotechnology Council of New Jersey. He is a trustee of the University
of Charleston. He received an AB from Dartmouth, a JD from Columbia and
a PhD from Princeton. Profile
Medarex?
Dr. Drakeman: Medarex was established in 1987 to develop monoclonal
antibody-based therapeutic products for
